Real world pharmacovigilance assessment of drug related macular degeneration risks by Xiaodong Chen, Shinan Wu, Shaopan Wang, Chaofeng Yu, Zihan Guo, Shiya Huang, Peixin Cai, Yanliang Miao, Shiying Li, Qian Chen

Subjects: Get full text

The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia by Kovačić Barbara, Pavičić Morana, Skvrce Nikica Mirošević, Tomić Siniša

Subjects: “…pharmacovigilance…”
Get full text

Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities by Nai Lee, Su‐jin Rhee, Seong Min Koo, So Won Kim, Gyo Eun Lee, Yoon A Yie, Yun Kim

Subjects: Get full text

Entangled evidence: epistemic injustice, and systemic neglect in the assessment of menstrual disorders following COVID-19 vaccines by Maurizia Mezza

Subjects: “…pharmacovigilance…”
Get full text

Knowledge, Attitude, Practice, and Barriers of Adverse Drug Reaction Reporting Among Healthcare Professionals in Timor‐Leste: A Cross‐Sectional Survey by Juanina daCosta, Wichit Nosoongnoen, Watcharee Rungapiromnan, Pramote Tragulpiankit

Subjects: Get full text

Role of the hospital pharmacists during COVID-19 pandemic in the RN Macedonia by Zorica Naumovska, Biljana Lazarova, Maja Kovaceva, Aleksandra Kapedanovska Nestorovska, Maja Simonoska Crcarevska, Evgenija Mihajloska, Aleksandar Dimkovski

Subjects: Get full text

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis by Hui Chen

Subjects: Get full text

A study on the pharmacovigilance of various SGLT-2 inhibitors by Yanwen Dong, Yangyang Wang, Yangyang Wang, Xiaomei Lan, Xiaomei Lan, Huiyan Zeng, Huiyan Zeng

Subjects: Get full text

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases by Xianyu Dai, Kai Yu, Yu Chang, Yuchuan Hou

Subjects: Get full text

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database by Peiyang Cao, Qian Wang, Yan Wang, Qing Qiao, Liyuan Yan

Subjects: Get full text

Ensuring safe and effective pharmacotherapy: The role of “community pharmacology” in attaining “health for all” from the Indian perspective by Tirthankar Deb, Alapan Das, Bisweswar Ojha, Prasanjit Das

Subjects: Get full text

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database by Bu-kun Zhu, Si-ying Chen, Xiang Li, Shu-yun Huang, Zhan-yang Luo, Wei Zhang

Subjects: Get full text

Adverse events in the nervous system associated with blinatumomab: a real-world study by Wen Gao, Jingwei Yu, Yifei Sun, Zheng Song, Xia Liu, Xue Han, Lanfan Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang

Subjects: Get full text

Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS by Ke Wang, Ke Wang, Junyan Chen, Mingquan Huang, Xinhao Zeng, Xiaoqun Ren, Xiuqiong Liu, Chao Tao, Chao Tao, Liuxuan Yang, Liuxuan Yang, Jinlu Shang, Meiling Zhou

Subjects: Get full text

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea by Taehyun Yang, Juhee Ahn, Juhee Ahn, Sungho Won, Sungho Won, Sungho Won, Sanghun Lee

Subjects: Get full text

Real-Time Pharmacovigilance: Transforming Population-Based Monitoring of Post-Approval Vaccine Safety Through Rapid Cycle Analysis (RCA)—A Review of the Published Literature by Sampada Gandhi, Michelle R. Iannacone, Andrea Leapley, Li Wang, Mwedusasa Mtenga, Muhammad Younus, Joanne Wu

Subjects: Get full text

Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system by Yixuan Yang, Hanzhang Xie, Shuhan Liu, Ying Jia, Bingnan Cui, Zhanshuo Xiao

Subjects: Get full text

Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system by Ying Zhao, Yuke Zhong, Liuqing Wu, Jiao Yan, Weitao Lu

Subjects: Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA... by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text